

Heart Failure



**Evaluation and Treatment for Heart Failure Patients**

(See page 7 in Guideline for information specific to HF patients with preserved systolic function.)

Evaluation						
<b>History:</b> Thorough assessment of functional status and activities of daily living <b>Physical:</b> Thorough assessment of volume state <b>Initial 12 Lead EKG</b>		<b>Initial Lab Tests:</b> CBC, UA, Electrolytes, BUN, Creatinine, Calcium, TSH, Liver Function Test, Glucose, Lipid Profile <b>Serial Monitoring:</b> Weight, electrolytes, renal function			<b>2D Doppler Echocardiogram</b> <b>Chest X-Ray:</b> PA + LAT <b>Evaluate For Ischemia:</b> Cardiac cath & angio: if angina present or revascularization is considered	
Treatment						
Classification (see page 7 for details)	ACC/AHA HF Stage	A*	B	C		D
	NYHA Functional Class	None	I	II	III	IV
<b>Medications</b>	<b>ACE Inhibitor</b>	For patients with diabetes, atherosclerosis. Consider for HTN or multiple risk factors	For all patients (Use of ACE inhibitors for patients with LVEF <40% is often used as a performance measure) Lack of evidence for ACE and ARB combination therapy			
	<b>ARB</b>	If ACE intolerant. Lack of evidence for ACE and ARB combination therapy				
	<b>Hydralazine/Long-Acting Nitrate</b>		If ACE or ARB intolerant; or in addition to standard triple therapy (in black patients) Standard triple therapy is ACEi or ARB, Beta Blocker, and Aldosterone Antagonist			
	<b>Beta Blocker<sup>a</sup></b>	In all patients				
	<b>Digitalis</b>	Consider for symptom relief or rate control—Target dig. level <1.0. If prescribed monitor dig. level, especially in the elderly				
	<b>Aldosterone Antagonists</b>	Consider in diabetics who are post-MI with EF<40%. Consider in other patients who also have evidence of CHF-(rales, abnormal CXR or S3) <sup>b</sup>	If Class II - IV symptoms, for patients with preserved renal function and normal potassium concentration <sup>c</sup> in non-diabetics with EF<35%			
	<b>Nitrates Alone or with Hydralazine</b>	Consider on top of ACE inhibitor, beta blocker, diuretic <sup>d</sup>				
	<b>Diuretics</b>	Current or recurring fluid retention				
	<b>Anticoagulants</b>	If AFib or previous thromboembolic event				
	<b>Influenza and Pneumococcal Vaccine</b>	In all patients				
	<b>Avoid Drugs that Potentiate HF</b>	In all patients (Drugs such as, but not limited to: NSAID, Glitzone, Enbrel)				
<b>Additional Treatment Considerations</b>	<b>Hypertension</b>	Control to guideline goals (<140/90 mm HG for ages <60; <150/90 for ages ≥ 60 mm HG with no diabetes and no kidney disease)				
	<b>Atrial Fibrillation</b>	Control rate; oral anticoagulant				
	<b>Weight Loss</b>	Recommended if BMI >25				
	<b>Exercise</b>	To tolerance, consider cardiac rehab to improve functional capacity				
	<b>Education - including caregiver(s)</b>	Disease process	Disease process, medications, signs to react to, daily weights, signs and symptoms of depression			
	<b>Restrict salt &amp; excess fluids</b>	In all patients to appropriate levels				
	<b>Cardiotoxins</b>	Avoidance of smoking, alcohol consumption, and illicit drug use				
<b>Referrals</b>	<b>Advance Care Directives</b>	For all patients				
	<b>Case/Disease Mgmt</b>	Monitor daily weights and close symptom surveillance (consider referral for nurse case mgmt)				
	<b>Telehealth Monitoring</b>	Consider use of telehealth monitoring services for selected patients				
	<b>Cardiovascular Specialist</b>	Consider to evaluate & treat as indicated	Consider to evaluate and optimize medical therapy; coronary revascularization; valve replacement/repair; implantable defibrillator; biventricular pacing			
	<b>Palliative Care</b>	As appropriate for symptom management				

a. Beta Blockers recommended for use with heart failure: carvedilol, metoprolol succinate, bisoprolol; b. EPHEsus study on eplerenone; c. Serum K+ and GFR should be monitored periodically; d. Nitrates with Hydralazine recommended in addition to standard therapy for all African-Americans with heart failure. \*No symptoms of heart failure, no structural heart disease

Guidelines are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines should be followed in most cases, but there is an understanding that, depending on the patient, the setting, the circumstances, or other factors, care can and should be tailored to fit individual needs.